GHRS

GHRS

GH Research PLC

Rev โ€”top 1%5Y
Hold

GH Research PLC is a clinical-stage biopharmaceutical company developing treatments for depression. Its lead products include inhalable GH001 for treatment-resistant depression and intravenous GH002 for psychiatric disorders, currently in trials.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$1,467today

Score Overview

1 Year
Scoreโ€”
Net Growth-29.04%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-4x
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-4x
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

GH Research PLC fundamental performance

Across GH Research PLC's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 9M to -$ 48M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 30.24โ€”
1 Year2025-08-12
$ 12.14149.09%
5 Years2021-08-12
$ 20.6146.72%
All Time2021-06-25
$ 19.2557.09%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 62M$ 362M
2025$ 0.00-$ 48M$ 280M
2024$ 0.00-$ 38M$ 149M
2023$ 0.00-$ 35M$ 161M
2022$ 0.00-$ 22M$ 165M
IPO2021$ 0.00-$ 9M$ 276M

Explore beyond GHRS

You're looking at GH Research PLC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies